The World Health Organization (WHO) announced the reclassification of the COVID-19 outbreak as a global pandemic on March 11, 2020. With the rapid spread of the disease across the globe, countries worldwide have joined the war against the SARS-CoV-2 virus, for which, early prevention, control, and treatment may provide valuable tools against the pandemic. Currently, research and development of treatment is of the highest priority. Accurate animal models are necessary for verifying the pathogenesis and immune mechanisms of the illness to accelerate research across vaccine development, new drug development, gene therapy, and more. As professional providers of animal models with a strong basis in social responsibility - since the outbreak, the R&D team at Cyagen has made every effort to develop animal models catered to the global SARS-CoV-2/COVID-19 research initiative, helping to accelerate progress to your next research breakthrough.
In the course of our decades-long fight against coronaviruses, researchers have studied the virus itself and its host receptors from various perspectives, such as epidemiology, pathological phenomena, viral tracing, prevention and control measures, etc. As a human receptor that binds to the spike (S) protein of SARS-CoV-2 to mediate host cell entry, functional investigation of angiotensin-converting enzyme 2 (ACE2) is particularly important. Effective immediately, Cyagen is opening orders on models for ACE2 receptor targets, including humanized, knockout (KO), and ROSA26 knockin (KI) mouse models.
|Price ($) per Mouse
|As Fast as 2 Months
|As Fast as 2 Months
| Humanized Mice
|As Fast as 2 Months
For more information, visit: ACE2 Humanized Mice – Expedite Your COVID-19 Research Efforts
At present, the prevention and treatment of the novel coronavirus is the most urgent issue for scientific and medical research. Herein, experts from Cyagen investigate the lesser-known targets that are pertinent to coronavirus research, aiming to provide some helpful references to guide scientific researchers.
|The Target’s Role in Viral Infections
(Aminope ptidase N)
(Transmembrane Serine Protease 2)
(ADAM Metallopeptidase Domain 17) KO/cKO/Humanized Mice
(Lymphocyte Antigen 6 Complex, Locus E) KO/cKO/Humanized Mice
(Cluster of Differentiation 209) KO/cKO/Humanized Mice
(Cluster of Differentiation 147) KO/cKO/Humanized Mice
(Dihydroorotate Dehydrogenase) KO/cKO/Humanized Mice
In addition to above targets, if you would like to order any other models related to the research of SARS-CoV-2 (COVID-19), our experts are readily available to provide you with a free targeting strategy, quote, and letter of support (useful in funding & grant applications) for your next model generation project. Contact us!
The COVID-19 pandemic has been a clear reminder that infectious diseases caused by human pathogenic viruses are still a huge threat to global public health and economic development. Continuous efforts to study the pathogenic mechanisms of such viruses, prevent the spread of viral infections, and develop new strategies for specific vaccines and antiviral drugs have been of paramount importance to the quick progress made against SARS-COV-2 infections and COVID-19.
The application of research animal models – such as inbred mice with clear genetic background, humanized mice with cell/tissue transplantation, and genetically engineered mice - not only helps to study the pathogenic mechanism of viruses, but further clarifies the role of specific genes in the development of infectious diseases. In addition, choosing the appropriate models can provide effective, convenient, and feasible platforms for in vivo experiments, providing relevant data for the evaluation of potential targets of value in the prevention and treatment of different viral pathologies.
Comparisons of both nucleic and amino acid sequences have confirmed a high similarity between SARS-CoV-2 and SARS-CoV (approximately 80% and 76%, respectively). Additionally, SARS-CoV-2 interacts with the host through the human ACE2 receptor on the cell surface to initiate infection and causes clinical manifestations similar to SARS-CoV infection (though not exactly the same). Due to the similarities between these two viruses, the research on SARS-CoV provides an important point of reference for SARS-CoV-2 research.
Whether your research involves SARS-CoV-2 related gene targets or factors in other cellular processes, Cyagen can provide the relevant gene knockout (KO), knock-in (KI), conditional knock-out (cKO), point mutation, and humanized mice models to facilitate your research goals. Our genetic engineering experts are readily-available to consult on your research project and provide you with a free targeting strategy, quote, and an official letter of support for your research funding applications.
If you would like more information about how we can support your custom animal model needs, please contact us.
One-stop solution for gene targeting mouse model
TurboKnockout® Knockout Mice: ES cell mediated, IP Free, As fast as 6 months, No off-target effects
CRISPR Cas9 Knockout Mice: As fast as 3 months, Guaranteed germline transmitted F1 mice
Transgenic Mice: Quick turnaround time, High expression level
PiggyBac Transgenic Mice: More consistent expression, Defined region of integration, As fast as 3 months
CRISPR Knockin Mice: Large fragment up to 8kb, As fast as 4 months